Orthofix Medical Inc

Orthofix Medical Inc (OFIX) Stock Analysis

$9.700

+0.071 (+0.73%)At close

Loading chart…
High
9.810
Open
9.640
VWAP
9.71
Vol
221.25K
Mkt Cap
505.89M
Low
9.610
Amount
2.15M
EV/EBITDA, TTM
5.09

Orthofix Medical Inc. is a global medical technology company. It offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System. Its Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. It provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation.

AI analysis of Orthofix Medical Inc (OFIX)

hold

Orthofix Medical Inc is currently trading at $9.70, which is significantly below the lowest analyst price target of $13, indicating potential upside. However, the stock has a low RSI of 34.59, suggesting it is oversold, but the recent 5-day change is down 3.10%, indicating continued weakness. The company has reduced its revenue guidance for 2026 to $845M-$855M, which is below the consensus of $843.31M, reflecting cautious market conditions. The main risk is the forward P/E ratio of 500, indicating potential overvaluation if earnings do not improve significantly in the near future.

Analyst Ratings (7)

+119.90% upside
Buy
6 Buy
1 Hold
0 Sell
Current: 9.70
Low
18.00
Average
21.33
High
24.00

Canaccord

2026-08-10

Price Target

$13

Buy

Barrington

2026-08-06

Price Target

$14

Outperform

Stifel

2026-08-05

Price Target

$13

Buy

Stifel

2026-03-09

Price Target

$18

Buy

Canaccord

2026-02-26

Price Target

$20

Buy

Valuation Metrics

The current forward P/E ratio for Orthofix Medical Inc (OFIX) is 500.00, compared to its 5-year average forward P/E of 8.52.

Forward P/E

Strongly Overvalued
5Y Average P/E
8.52
Current P/E
500.00
Overvalued
160.96
Undervalued
-143.92

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
9.11
Current EV/EBITDA
5.09
Overvalued
11.87
Undervalued
6.36

Forward P/S

Undervalued
5Y Average P/S
0.81
Current P/S
0.45
Overvalued
1.10
Undervalued
0.52

Alphio AI Price Scenarios for OFIX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%OFIX

$10.69

Scenario price

B

Base

Base · 50%OFIX

$10.56

Scenario price

B

Bear

Bear · 25%OFIX

$10.47

Scenario price

Whales holding OFIX

A

Armistice Capital LLC

+ HoldingOFIX

+13.92%

3M Return

P

Paradigm Capital Management, Inc.

+ HoldingOFIX

-14.65%

3M Return

Events Timeline

2026-08-05 (ET)

07:30:00

Orthofix Reports Q2 Revenue of $210.9M, Beating Expectations

07:30:00

Orthofix Raises 2026 Net Sales Guidance to $845-$855 Million

2026-07-06 (ET)

09:00:00

Nasdaq and S&P 500 Futures Rise as Chip Stocks Rebound

08:00:00

Orthofix Expects Medicare Reimbursement to Return to Pre-2026 Levels

2026-05-21 (ET)

10:00:00

Orthofix Updates 2026 Financial Outlook, Expects Net Sales of $838M to $848M

News

OFIX FAQ — answered by Alphio AI

Orthofix Medical Inc. is a global medical technology company. It offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System. Its Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. It provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Orthofix Medical Inc is currently trading at $9.70, which is significantly below the lowest analyst price target of $13, indicating potential upside. However, the stock has a low RSI of 34.59, suggesting it is oversold, but the recent 5-day change is down 3.10%, indicating continued weakness. The company has reduced its revenue guidance for 2026 to $845M-$855M, which is below the consensus of $843.31M, reflecting cautious market conditions. The main risk is the forward P/E ratio of 500, indicating potential overvaluation if earnings do not improve significantly in the near future.

7 analysts cover OFIX: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 21.33.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始